The Cochrane Abstract below is a su...

The Cochrane Abstract below is a summary of a review from the Cochrane Library. It is accompanied on an interpretation to help clinicians bring evidence into practice. Dan Brewer, MD instants a clinical scenario and question based forward the Cochrane Abstract, along with an evidence-based answer and a replete critique of the abstract.

Clinical Scenario

A 70-year-old man with normal sinus metre had a thrombotic stroke that ariseed in weakness in his non-dominant hand and leg

Clinical Question

Should this patient receive long-term anticoagulation to improve function or model the possibility of recurrent vascular conclusions and death?

Evidence-Based Answer

There is no evidence that anticoagulation with either heparin or warfarin improves these consequences There is clear evidence of increased hemorrhagic complications (both fatal and nonfatal) in patients who receive anticoagulation.

Cochrane Critique

Did the author address a focused clinical question? Ye Several other reviews in the Cochrane calamity Group address specific issues like as acute anticoagulation, anticoagulant versus antiplatelet therapy, and anticoagulation in atrial fibrillation.

Were the criteria used to preferable articles for inclusion appropriate? Yes

Is it likely that important relevant articles were missed? No. A search for unpublished articles, including those from relevant pharmaceutical manufacturers, was conducted

Was the validity of the individual articles appraised? Yes

Were the assessments of studies reproducible? Yes

Were the flows similar from study to study? Yes

for what reason precise were the results? The ends on hemorrhage, recurrent stroke, and death are robust. Other period points, such as recurrent vascular circumstances and function, are more difficult to base conclusions in succession because of the differing definitions and modes of the included trials.

Can the inferences be applied to patient care? Yes

Do the conclusions make clinical and biologic sense? Yes

Are the benefits worth the harms and costs? The review commits against this intervention, so no extra splendor is involved. There are significant sumptuousness savings.

Practice Pointers

There are about 46 million calamity survivors in the United States today, and 600000 nation have new strokes each year. These patients are at increased risk of returning stroke, other vascular events, adjunct and death. (2) Patients whose attacks had a cardioembolic source (eg atrial fibrillation) generally should receive anticoagulation for secondary prevention, yet the appropriate treatment is more controversial in patients with thrombotic attacks One survey (3) noted that 53 percent of randomly gooded U.S. physicians always or ofttimes prescribe an anticoagulant for patients with transient ischemic attack or latter minor stroke.

This review point outs that there is no convincing evidence that protracted anticoagulation is beneficial following presum noncardioembolic blow or transient ischemic attack. There is, however, convincing evidence that anticoagulation increases the rate of fatal intracranial hemorrhages and major extracranial hemorrhages. A separate Cochrane review (4) and a novel joint American Heart Association/American Academy of Neurology committee (5) set no evidence of benefit from anticoagulation within 48 hours from the storm of stroke. A third Cochrane review (6) plant no additional benefit from adding anticoagulant therapy to antiplatelet therapy.

Anticoagulant therapy has a narrow therapeutic window and is a difficult regimen to manage in a consistently safe manner. This is especially genuine in elderly patients, who have a higher rate of hemorrhagic complications and who oftentimes are on complex medical regimens with increased risk of drug-drug interactions. Although as physicians we want to be able to intervene to shorten the suffering of patients with pat the best course is to use antiplatelet therapy instead of anticoagulation.

REFERENCES

(1) Sandercock P Mielke O Liu M Counsell C Anticoagulants for preventing resort following presumed non-cardioembolic ischaemic shock or transient ischaemic attack. Cochrane Database Syst Rev 2003:CD000248

(2) American Heart Association. 2002 heart and affliction statistical update. Dallas, Tex.: The Association, 2001

(3) Goldstein LB Farmer A, Matchar DB Primary care physician-reported secondary and tertiary reverse prevention practices. A comparison between the United States and the United Kingdom. thump 1997;28:746-51.

(4.) Gubitz G Counsell C Sandercock P Signorini D Anticoagulants for acute ischaemic reverse Cochrane Database Syst Rev 2003:CD000024

(5) Coull BM Williams L Goldstein LB Meschia JF Heitzman D Chaturvedi s et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint rap Guideline Development Committee of the American Academy of Neurology and the American reverse Association (a division of the American Heart Association). thump 2002;33:1934-42.

(6.) Berge E Sandercock P Anticoagulants versus antiplatelet agents for acute ischaemic visitation Cochrane Database Syst Rev, 2003:CD003242